Flaherty Keith T. 4
4 · Checkmate Pharmaceuticals, Inc. · Filed May 31, 2022
Insider Transaction Report
Form 4
Flaherty Keith T.
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−4,012→ 0 totalExercise: $2.47Exp: 2028-03-27→ Common Stock (4,012 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−10,030→ 0 totalExercise: $6.27Exp: 2031-06-16→ Common Stock (10,030 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−22,736→ 0 totalExercise: $2.62Exp: 2029-03-27→ Common Stock (22,736 underlying)
Footnotes (1)
- [F1]At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.